WEE1 Inhibitor AZD1775, External Beam Radiation Therapy, and Cisplatin in Treating Patients With Cervical, Vaginal, or Uterine Cancer
Conditions: Endometrioid Adenocarcinoma; Recurrent Cervical Carcinoma; Stage I Uterine Corpus Cancer; Stage I Vaginal Cancer; Stage IA Uterine Corpus Cancer; Stage IB Cervical Cancer; Stage IB Uterine Corpus Cancer; Stage II Cervical Cancer; Stage II Uterine Corpus Cancer; Stage II Vaginal Cancer; Stage IIA Cervical Cancer; Stage IIB Cervical Cancer; Stage III Cervical Cancer; Stage III Uterine Corpus Cancer; Stage III Vaginal Cancer; Stage IIIA Cervical Cancer; Stage IIIA Uterine Corpus Cancer; St age IIIB Cervical Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer Interventions: Drug: Cisplatin; Radiation: External Beam Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: WEE1 Inhibitor AZD1775 Sponsor: National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinoma | Cervical Cancer | External Beam Therapy | Radiation Therapy | Study